Most people assume Ozempic came out of a pharmaceutical lab somewhere in Denmark, the product of decades of carefully controlled human science. The reality is stranger and, honestly, more fascinating. The story of how this drug came to exist runs through the desert Southwest of the United States, through the jaws of a slow-moving, venomous lizard that eats just a handful of times a year. And the further you go into that origin story, the harder it becomes to separate the wonder of the science from the very real questions about what this drug does to the human body.
Right now, roughly one in seventeen Americans is on a GLP-1 drug. Ozempic is the name most of them know. It’s been celebrated, debated, sued over, and prescribed at a scale that clinical medicine rarely sees this fast. Before the drug existed, the lizard came first.
Understanding both is the only way to make sense of what you may be putting in your body every week, and why the full picture of its Ozempic side effects is still being written.
From Desert Venom to Doctor’s Office
VA researchers made a discovery that would change metabolic medicine. In the mid-1990s, Drs. John Eng and Jean-Pierre Raufman found that a hormone in the venom of the Gila monster, a large lizard native to the southwestern United States, stimulates the body’s insulin production. Dr. Eng’s interest was sparked when he learned that the Gila monster, after long periods of not eating, is able to slow down its metabolism and maintain constant blood sugar levels without affecting its health.
He assayed the venom and discovered a peptide that triggers synthesis and release of insulin from beta cells in the pancreas. To his surprise, Dr. Eng found that exendin-4 was similar in both structure and function to GLP-1, a hormone found in the human gut that stimulates insulin production, but only when blood glucose is elevated. The biological logic was elegant: the Gila monster had evolved a molecule that solved a problem pharmacologists had been wrestling with for years.
The key advantage was durability. Exendin-4 showed structural similarity to human GLP-1, sharing approximately 53% sequence homology, and this peptide in the venomous saliva of this southwestern lizard mimics human GLP-1 hormone but resists rapid breakdown. GLP-1 itself remains active in the human body for only a matter of minutes. Exendin-4, by contrast, remains active for hours, suggesting it could be a long-acting, effective diabetes treatment.
A synthetic version of exendin-4, called exenatide, was approved for medical use by the FDA in 2005. Exenatide, sold commercially as Byetta or Bydureon, is taken as a shot by people with type 2 diabetes. According to Drugs.com’s FDA approval history, Byetta received its formal approval on April 28, 2005. These medications remain the direct pharmaceutical descendants of the original venom discovery.
Ozempic Is Not Lizard Venom, But the Lizard Made It Possible
Ozempic itself is a synthetic modification of human GLP-1 rather than a direct derivative of Gila monster venom. The lizard’s biology, however, provided the crucial blueprint for this entire class of medicines. Semaglutide, the active ingredient in Ozempic, is a synthetic GLP-1 analogue modified for once-weekly dosing and enhanced albumin binding, with a much closer structural resemblance to the human hormone than to the original lizard peptide.
The FDA approved Ozempic for type 2 diabetes in December 2017. Its rise from diabetes drug to cultural phenomenon happened remarkably quickly. Ozempic, a GLP-1 receptor agonist used to manage type 2 diabetes, works by mimicking GLP-1 to help regulate blood glucose levels while also curbing appetite.
The results in clinical trials were difficult to ignore. According to the European Medicines Agency, clinical studies in over 4,000 patients showed Ozempic lowered HbA1c (a measure of long-term blood glucose control) by between 1.2 and 1.8 percentage points over 10 to 13 months. On top of that, data published in 2026 shows the drug helps people lose an average of 12 to 15% of their body weight. And in January 2025, the FDA expanded Ozempic’s approval to include reducing the risk of kidney disease progression and cardiovascular death.
The cardiovascular data has been particularly striking. The SELECT trial showed that a 20% reduction in major adverse cardiovascular events was possible in people who were overweight or obese with existing heart disease. Perhaps most surprising, researchers found those cardiovascular benefits were already evident within the first six months of treatment, before patients had reached their maximum weight loss.
The Side Effects That Don’t Make the Ads
The efficacy story is real. So is the side effect story, and the two deserve equal attention.
The most common Ozempic side effects are nausea, diarrhea, abdominal pain, vomiting and constipation, according to the drug’s prescribing information. For most people, these gastrointestinal side effects tend to subside after dose adjustment. But for a meaningful minority, the problems are more persistent and more serious.
Ozempic has an FDA boxed warning for thyroid C-cell tumors, medullary thyroid carcinoma, and multiple endocrine neoplasia type 2 (MEN 2). The most serious Ozempic side effects also include pancreatitis, gastroparesis (stomach paralysis), and acute kidney injury.
Gastroparesis deserves particular attention. The drug works in part by slowing how quickly the stomach empties its contents, which helps control blood sugar after meals. As a GLP-1 receptor agonist, Ozempic slows stomach emptying to help regulate blood sugar, which may lead to gastrointestinal complications. People taking semaglutide showed a higher risk of gastroparesis than those receiving other weight-loss treatments, with the risk roughly three times higher compared to those taking a different weight-loss drug called bupropion-naltrexone. Despite these comparisons, researchers noted that the side effect remains rare in absolute terms.
The regulatory picture has been moving fast. In October 2025, the FDA updated Ozempic’s warning label to highlight the risk of serious pancreas and stomach problems. The label also says Ozempic is not recommended for people with severe stomach paralysis (gastroparesis).
The Eye Risk You Haven’t Heard Enough About
One side effect that has attracted significant regulatory attention in the past year is an eye condition most people have never heard of. In June 2025, European regulators added non-arteritic anterior ischemic optic neuropathy, or NAION, as a very rare side effect on the Ozempic label. NAION is a serious eye condition that can cause sudden, permanent vision loss when blood flow to the optic nerve is disrupted. The updated warning instructs patients to stop taking Ozempic immediately if they notice sudden changes in vision and to seek urgent medical care.
A large multicenter study of 37.1 million adults with type 2 diabetes across 14 databases identified a small increase in the relative incidence of NAION from exposure to semaglutide compared with nonexposure. The findings provide further evidence of an association between semaglutide and NAION but show a smaller risk than previously reported, with additional studies necessary to identify potential mechanisms and causality. This study was published in JAMA Ophthalmology in April 2025.
According to a systematic review also published in JAMA Ophthalmology, semaglutide showed no significant associations with the risk of diabetic retinopathy or general ocular disorders, although significant increases were seen in the risk of NAION. More studies are needed to understand the full picture and identify which patients carry the highest risk.
This is not a reason to panic, but it is a reason to tell your eye doctor you’re on this medication. Anyone who notices sudden changes in vision while taking Ozempic should treat it as a medical emergency.
What Real-World Users Are Reporting
Researchers at the University of Pennsylvania’s School of Engineering and Applied Science used AI to analyze more than 400,000 Reddit posts, identifying patient-reported symptoms associated with GLP-1 drugs that may not be fully captured in clinical trials. Published in Nature Health, the study spans more than half a decade of posts from nearly 70,000 Reddit users and found two primary categories of symptoms warranting deeper investigation: reproductive symptoms, including irregular menstrual cycles, and temperature-related complaints such as chills and hot flashes.
The study does not establish causation and carries significant methodological limitations, but it represents a new approach to pharmacovigilance, the science of monitoring drug safety after approval, powered by the scale and candor of social media.
The FDA has also investigated reports of hair loss and suicidal thoughts linked to Ozempic. As of May 2026, the FDA Adverse Event Monitoring System showed 659 reports of alopecia (hair loss) and 389 reports of suicidal ideation linked to the drug. While there have been concerns over the drug leading to suicidal ideation, a preliminary FDA evaluation failed to find evidence that Ozempic caused suicidal thoughts or tendencies. These are reports, not confirmed causal links. They are, however, worth discussing with your prescriber before starting treatment.
Who Gets the Best Results, and Why
Not everyone loses the same amount of weight on semaglutide, and researchers are beginning to understand why. According to a 2026 meta-analysis from Johns Hopkins, women lost approximately 11% of their starting weight on GLP-1 drugs compared to about 7% among men.
The reasons behind this variability may run deeper than body composition. NIH research published in 2026 found that semaglutide triggers different responses inside appetite-controlling brain cells, which may help explain why some patients see dramatic results while others plateau early.
And speaking of plateaus: research published in 2026 found that weight loss typically plateaus after approximately one year of semaglutide treatment, with weight regain often beginning to emerge in the second year. This doesn’t mean the drug stops working entirely, but it does mean the expectations patients carry into treatment often don’t match long-term reality.
For people who need more aggressive weight loss, tirzepatide, sold as Zepbound or Mounjaro, delivers the most substantial weight reduction among drugs in this class. The SURMOUNT-1 trial reported mean weight reductions of 15% to 20.9% at 72 weeks, significantly surpassing previous pharmacotherapies.
Read More: GLP-1 Drugs and Unlisted Side Effects: What Reddit Is Telling Researchers
What This All Means
Ozempic is one of the most effective tools in modern metabolic medicine. It grew from a genuinely remarkable scientific story, one that began with a biochemist studying a desert lizard, and the medications it inspired have changed outcomes for millions of people with diabetes and obesity. The cardiovascular and kidney data are among the most compelling findings in recent endocrinology.
But the Ozempic side effects story is not finished. The gastrointestinal risks are real, the vision concerns are being taken seriously by regulators, and real-world surveillance is turning up questions that clinical trials were never designed to catch. Ozempic represents both a medical opportunity and a regulatory work in progress. It is effective, but surrounded by ongoing debates about safety, unauthorized versions, and limited long-term evidence.
If you’re taking Ozempic or considering it, the most useful thing you can do is have an honest conversation with your doctor about your full medical history, including any history of pancreatitis, thyroid conditions, eye problems, or gastroparesis symptoms. Report any new symptoms promptly, and don’t dismiss sudden changes in vision as something that will pass. Know that the drug works differently for different people, that weight loss typically plateaus around the one-year mark, and that stopping the medication often means regaining weight without a longer-term management plan in place.
The lizard that inspired all of this eats just a few times a year and never seems to struggle with blood sugar. For humans, the biology is a great deal more complicated. Use the science, but use it with your eyes open.
Disclaimer: This information is not intended to be a substitute for professional medical advice, diagnosis, or treatment and is for information only. Always seek the advice of your physician or another qualified health provider with any questions about your medical condition and/or current medication. Do not disregard professional medical advice or delay seeking advice or treatment because of something you have read here.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.